We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01030406
Recruitment Status : Completed
First Posted : December 11, 2009
Last Update Posted : March 10, 2010
Information provided by:

Study Description
Brief Summary:
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent recreational opioid users.

Condition or disease Intervention/treatment Phase
Opioid Abuse Drug: Drug A Drug: Drug B Drug: Drug C Drug: Drug D Drug: Placebo Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 47 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Study Start Date : January 2010
Primary Completion Date : February 2010
Study Completion Date : February 2010
Arms and Interventions

Arm Intervention/treatment
Active Comparator: Treatment A Drug: Drug A
Active Comparator: Treatment B Drug: Drug B
Experimental: Treatment C Drug: Drug C
Experimental: Treatment D Drug: Drug D
Placebo Comparator: Treatment E Drug: Placebo

Outcome Measures

Primary Outcome Measures :
  1. Drug Liking/Disliking analyzed over 0-3 hours [ Time Frame: collected at 0.5,1,1.5, 2,3,4,5,6,8, and 12 hours post-dose ]

Secondary Outcome Measures :
  1. Take Drug Again Assessment (TDAA) [ Time Frame: 1, 2, and 8 hours post-dose ]
  2. Global Assessment of Overall Drug Liking [ Time Frame: 12 hours post-dose ]
  3. Pupillometry [ Time Frame: pre-dose and 0.5,1,1.5,2,3,4,5,6,8, and 12 hours post-dose ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject is male or female between 18 and 55 years old.
  • Subject is in generally good health, including no history of pulmonary disease, and has a body mass index (BMI) within 18-33 kg/m2.
  • Subject is a recreational opioid user (i.e., at least 10 occasions within the past 12 months, and at least 1 within the past 12 weeks) who is NOT physically dependent on opioids (per Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision [DSM-IV-TR]); is able to speak, read, and understand English; and will provide written informed consent.
  • Subject has a minimum of a 6th grade reading level as determined by the Investigator or by the Rapid Estimation of Adult Literacy in Medicine (REALM).

Exclusion Criteria:

  • History or current diagnosis of substance dependence (except nicotine and caffeine) and/or alcohol abuse according to the criteria of DSM-IV-TR.
  • History or current diagnosis of neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, hematologic, pulmonary, or metabolic disease.
  • Known allergy or history of hypersensitivity to oxycodone HCl, other opioids, or any component of Acurox Tablets.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01030406

United States, Utah
Lifetree Clinical Research
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Acura Pharmaceuticals Inc.
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
More Information

Responsible Party: Andy Reddick, CEO, Acura Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01030406     History of Changes
Other Study ID Numbers: AP-ADF-114
First Posted: December 11, 2009    Key Record Dates
Last Update Posted: March 10, 2010
Last Verified: March 2010

Keywords provided by Acura Pharmaceuticals Inc.:
Abuse Liability
Abuse Prevention
Abuse Resistance
Abuse Deterrence